Abstract: Bietti crystalline dystrophy (BCD) is a rare-inherited disease caused by mutations in the CYP4V2 gene and characterized by the presence of multiple shimmering yellow-white deposits in the posterior pole of the retina in association with atrophy of the retinal pigment epithelium (RPE) and chorioretinal atrophy. The additional presence of glittering dots located at the corneal limbus is also a frequent finding. The CYP4V2 protein belongs to the cytochrome P450 subfamily 4 and is mainly expressed in the retina and the RPE and less expressed in the cornea. The disease has its metabolic origin in the diminished transformation of fatty acid substrates into n-3 polyunsaturated fatty acids due to a dysregulation of the lipid metabolism. In this review, we provide updated insights on clinical and molecular characteristics of BCD including underlying mechanisms of BCD, genetic diagnosis, progress in the identification of causative genetic and epigenetic factors, available techniques of exploration and development of novel therapies. This information will help clinicians to improve accuracy of BCD diagnosis, providing the patient reliable information regarding prognosis and clinical prediction of the disease course.
Introduction
Bietti crystalline dystrophy ((BCD), Online Mendelian Inheritance in Man (OMIM) OMIM210370) is an inherited autosomal recessive disease linked to biallelic mutations affecting the CYP4V2 gene. Professor Gian Battista Bietti first described the disorder in 1937, 1 reporting three patients -including two brothers -with a pattern of retinal crystalline spots in the posterior pole, scattered conglomerations of retinal pigment, chorioretinal atrophy and corneal superficial deposits at the limbus. In addition, the author suggested the inherited and familial nature of the disease and differentiated it from other dystrophies like retinitis punctata albescens and fundus albipunctatus. Bagolini and Ioli-Spada 2 designated this pathology "Bietti´s tapetoretinal degeneration with marginal corneal dystrophy" and studied the evolution of these brothers and six additional patients in 1968, confirming the progressive and degenerative nature of their condition. Welch 3 introduced the term "crystalline retinopathy" in 1977 to complete the original description, and identified the presence of lipid inclusions in fibroblasts and corneal epithelium by analyzing a corneal limbus biopsy obtained from a patient with BCD, pointing to a metabolic involvement in the genesis of the disease. In 2000, Jiao et al 4 performed genetic linkage analysis to 49 members of 10
Chinese, Japanese and European families with BCD, and identified the locus of the gene responsible on human chromosome 4q35-qter. In 2004, at a later stage, studying the first cousin parents of an epidemiologic survey in China in 1983. In accordance with the works of Hartong et al 8 , Okialda et al 9 and Ng et al, 10 the estimated a prevalence of BCD is 1 in 67,000 individuals, affecting 21,000 patients in China and about 5000 in USA. According to our estimations, the actual prevalence of BCD in Spain may be extremely low, affecting approximately 1 in 4,500,000 subjects, ie, 10-12 cases in the whole country, based on a survey carried out in 2013 in more than 650 medical centers of Spain. 11 At the same time, the disease presents worldwide distribution, and tends to be common in the east of Asia, being more prevalent in Chinese, Japanese and Korean populations. Most of the reported cases diagnosed in Europe correspond to Italian, Lebanese and Spanish patients suggesting a possible Mediterranean distribution of the disease.
Onset, staging and clinical manifestations
BCD is a progressive chorioretinal dystrophy with corneal involvement characterized by profuse yellowish sparkling deposits at the retina (Figure 1 ), geographical areas of atrophy of the retinal pigment epithelium (RPE) and loss of choriocapillaris, chorioretinal atrophy and crystalline deposits in peripheral cornea. According to Yuzawa et al 12 , the illness can be classified into three stages ( Figure 2 ): Stage 1: RPE atrophy with crystalline deposits in the macular area.
Stage 2: RPE atrophy extends beyond the posterior pole. Choriocapillaris atrophy at the posterior pole. Crystalline confluent deposits in the damaged area, less in number at the advanced atrophic areas of the RPEchoriocapillaris complex.
Stage 3: RPE-choriocapillaris complex extensive atrophy and a small number of residual crystalline deposits throughout the fundus.
The first clinical manifestations most commonly appear between the second and third decade of life, but can develop from teenagers to over fourth decade, remaining the determinants of age at onset unclear. In addition, the severity of the retinal damage does not seem to correlate well with the age of debut.
During the earliest stages, patients with BCD are often asymptomatic, which difficult its diagnosis. Therefore, most early BCD cases are often diagnosed as casual findings. As BCD progresses symptoms appear slowly and painlessly, involving nyctalopia, limited peripheral vision and visual field constriction, color vision impairment, floaters, photopsias and monocular diplopia. In the late stages of BCD, severe visual damage and legal blindness are common findings. It should be kept in mind that disease evolution may be asymmetric in the two eyes, that a good visual acuity outcome may not correspond to the measure of damage in the retina and that high variability in disease presentation and evolution has been reported.
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Diagnosis
Corneal involvement: medical imaging techniques and clinical application
The presence of crystalline deposits in the peripheral paralimbal cornea is the main BCD clinical manifestation regarding the ocular surface, which might be explained by the moderate CYP4V2 expression in the corneal epithelium and subepithelium. 14 Functional deterioration of this gene carries an increased accumulation of intracellular deposits of fatty acids in peripheral corneal and conjunctival fibroblasts and keratinocytes, [15] [16] [17] involving the development of the marginal keratopathy. These subclinical alterations course with normal vision and are not essential requirements for BCD diagnosis. They are more commonly described in European than in Asian patients, although the reported frequency of marginal keratopathy is highly variable, ranging from a 75% rate of incidence in Spanish patients 11 to the complete absence of keratopathy in a sample of 15 Italian patients. 18 The presence of corneal crystalline deposits in the clinical reports and the identified mutations associated with them are summarized in Table 1 . The high quality of modern slit lamps allows the easy and quick identification of crystalline deposits throughout the entire peripheral cornea (Figure 3 ). Nevertheless, very ( Figure 5 ). Indocyanine green angiography (ICGA) remains considered as a valuable supplement diagnosis technique of BCD, better than FA in outlining the atrophy areas and in evidencing the real level and magnitude of the choroidal circulatory damage. 23, 24 Early-phase ICGA shows a significant delay in the filling of the choroidal vessels in every stage of the disease. This delay increases and correlates with BCD severity. An initial damage of the parapapillary area appeared to be constant by ICGA, showing a later centrifugal pattern of involvement as BCD progresses. In the middle stages, damage of the inner choroid increases and lobular hypofluorescent lesions become evident. 23, 24 Late-phase ICGA also reveals a more variable pattern of hyperfluorescence in clearly delimitated choroidal areas in all stages of BCD.
However, these two procedures are invasive and timeconsuming, requiring venipuncture, and are not free of risks and threats like anaphylaxis or even death related to FA and ICGA injections. In fact, its use has diminished considerably in the last years due to the development of new non-invasive high-resolution imaging techniques like spectral-domain optical coherence tomography angiography (SD-OCT-A). Fundus auto fluorescence (FAF) is not helpful to assess and control the evolution of crystalline deposits, because these dots present neither hypo-AF nor hyper-AF nature. The peripheral retina presents a normal FAF as long as there is no damage, but in BCD the posterior pole and the paracentral retina develops hypo-AF and clearly defined confluent-patched areas corresponding to local RPE loss sections. These alterations correlate well with funduscopic and FA changes throughout the progressive evolution of BCD. 25, 26 SD-OCT has proven to be an effective noninvasive retinal imaging method for evaluating the morphological and functional changes in BCD. Outer retinal tubulations (ORTs) and glistening hyperreflective deposits seem to be the main SD-OCT manifestations in BCD 25, 27 ( Figure 6 ).
ORTs are spherical hyporeflective lesions surrounded by a halo of high reflectivity, mainly situated in the retina outer nuclear layer and more frequent in advanced stages 2 and 3 of Yuzawa. 12 The mechanisms underlying ORTs remain unclear, but it has been suggested the existence of a diminished adherence of the photoreceptors outer segments to the RPE in its junction layer. 26, 29 This alteration can be due to a potential rearrangement and subsequent invagination of damaged photoreceptors that partially retain their function as a protection mechanism. The presence of crystalline glistening deposits has been confirmed in all retinal layers by SD-OCT, mainly in the outer retina, being more numerous at the RPE-choriocapillaris level, including the Bruch membrane. 20, 25 According to Saatci et al 28 , there are three categories of glistening deposits in SD-OCT sections: 1) highly reflective spots in the inner retina, 2) reflective plaques on the top of the Bruch membrane and 3) partially encapsulated reflective plaques. There seems to be a clear correlation between funduscopy crystalline deposits and hyperreflective dots located in or on REP-Bruch membrane complex. [25] [26] [27] [28] [29] [30] The origin and clinical significance of the plaques, encapsulated lesions and other hyperreflective dots, including those located in the choroid, remains unclear. Accumulation of protein deposits or inflammatory cells, glial response due to retinal destruction or even artifacts, has been postulated to explain the origin of these lesions. 25, 28 There are three potential phases in the evolution of BCD, according to SD-OCT imaging modality as defined by Li et al. 26 Structures with the appearance of druses, decrease of the interdigitating area and local disruption of the ellipsoid area are present in stage 1. Stage 2 involves the presence of isolated islands of remaining RPE in the context of a high loss of this retinal layer and damage of the outer retina. Severe macular disturbance is the main finding in stage 3. According to a recent study, 31 near-infrared imaging (NIR) -a commonly performed capture modality while acquiring simultaneous OCT scans -should be a useful tool in identifying BCD crystalline retinal deposits and in differentiating them from other presents in chorioretinal dystrophies with similar phenotypes, facilitating a more efficient posterior genetic diagnosis.
The knowledge of choroidal vasculature changes in retinal dystrophies has been especially improved by the use of OCT-A, a recent tool based on motion contrast imaging. The dynamic of the retinal and choroid microvasculature in BCD can be evaluated throughout the association of the advantages of the OCT-A and the split spectrum amplitude-decorrelation angiography.
A diminished choriocapillaris blood flow appears to be present in the vast majority of the BCD patients, and the visibility of the choriocapillaris layer at the subfoveal area correlates well with the degree of function of the visual system in BCD individuals according to Miyata et al. 32 These features make OCT-A a non-invasive and accessible alternative to assess the patient's evolution. Choroidal neovascularization has occasionally been reported in patients with clinical and molecular diagnosis of BCD. 26, [33] [34] [35] The nature and mechanisms of this relationship remain unclear, but RPE defects and long-term friction of the Bruch's membrane by the crystalline dots should play a reasonable role. 35 There is proven efficacy of anti-Vascular Endothelial Growth Factor (VEGF) therapy in the management of this complication. 34 Macular hole may also be detected in BCD and can be successfully managed by routine surgery. 36 In summary, the current available imaging techniques open up many possibilities to assess retinal dystrophies, and multimodal evaluation of BCD patients is strongly recommended in the management of the disease. These combined techniques should allow us to make the diagnosis as early as possible, staging the severity and the progression of the disease and monitoring the response to potential future treatments.
Electrophysiological findings
Electrophysiological techniques are objective complementary explorations in BCD that include full-field electroretinography (ffERG) and multifocal electroretinography (mfERG) recorded according to the ISCEV protocols. Regarding the electrooculogram, we consider it provides no additional information if ffERG and mfERG are performed. Actually, electrophysiology provides supplementary data in the early diagnosis, allows disease severity assessment, facilitates control of progression and determines how much retinal damage has been caused. The progression of the disease may follow a similar rodcone dystrophy pattern according to ffERG findings.
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Full-field ERG records range from normal in early stages to undetectable signals in the last phases of BCD. In the middle stages, the malfunction of both rod and cone mechanism involves multiple disturbances, and delayed amplitude of photopic and more evident scotopic responses should be present. 
Genetic diagnosis
The classical diagnosis of BCD based on the clinical findings of typical crystalline deposits in the retina and the cornea detected by an experienced physician is, in general, useful but did not provide assurance. However, the only way to confirm a diagnosis of BCD disease is the identification of CYP4V2 gene (OMIM, *608614) mutations by genetic analysis. The DNA samples can be simply obtained from peripheral leukocytes by venipuncture or by collection of a small amount of saliva into a sterile tube. Amplification of the 11 CYP4V2 exons, including intronexon junctions and flanking sequences, using PCR and followed by automated Sanger DNA sequencing can be performed as described by Li et al. 5 The complete genetic sequence can be also obtained by next-generation techniques, although the presence of a pathogenic variant needs confirmation by Sanger sequencing, which is considered the gold standard procedure in mutation detection. The 14, 17, [48] [49] [50] The ω-6 biosynthesis pathway apparently was not affected. 15 In serum, a reduced activity of the Δ-9-desaturase enzyme and abnormally low concentration of total monounsaturated fatty acids have been reported. 16, 50 The CYP4V2 enzyme is present predominantly in the endoplasmic reticulum of the human RPE cell line ARPE-19. Immunohistochemistry analyses revealed that CYP4V2 is also present in retinal outer and inner nuclear layers, retinal ganglion cells and corneal epithelial cells, in accordance with the BCD phenotype.
14 In addition, the gene is expressed in different non-ocular organs such as heart, lung, liver, pancreas, kidney, brain, skeletal muscle and placenta. Interestingly, BCD patients do not show any pathological condition in these organs, suggesting the presence of compensatory enzymes which are absent in the RPE. Moreover, the exact pathogenic mechanism involved in RPE malfunction and in the subsequent damage remains unknown. Particularly interesting is the function of the CYP4V2 protein in DHA reactions. DHA is an essential constituent of the rod outer segment and plays an important role in the maturation and survival of the photoreceptors cells required for normal visual function. 51 Functional CYP4V2 alteration generates a disruption of the membrane processing of lipids in RPE layer, which result in a significant focal dyslipidemia and degeneration of the photoreceptors. The endogenous conversion of DHA to resolvins, protectins and maresins 52 mediators involved in the innate anti-inflammatory modulation -suggests that defective CYP4V2 activity may also impair the resolution phase of the inflammatory process.
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Recently, Hata et al 53 performed the induction of pluripotent stem cells from individuals who carried specific CYP4V2 mutations to generate RPE cells, in order to develop an innovative in vitro model of BCD. These cells showed vacuolated cytoplasm similar to those degenerative changes observed in individuals with BCD. In addition, the cells accumulated glucosylceramide and free cholesterol in association with lysosomal malfunction and decay of autophagy flux, involving severe impairment and cellular apoptosis. The reduction of intracellular free cholesterol might mitigate the damage caused by BCD in RPE cells, and is postulated by the authors as a potential preventive or therapeutically measure.
BCD-associated gene variants
To date, over 100 disease-causing mutations in CYP4V2 gene have been reported according to previous clinical studies ( Table 2 ). The vast majority of the mutations are missense, followed by large deletions, nonsense mutations, small insertions or deletions and splicing site variants, which are more unusual. The most frequent mutation identified is the insertion-deletion IVS6-8del17bp/insGC or c.802-8del17bp/insGC, at the junction between intron 6-exon 7 of CYP4V2 gene, 54 59 is to the best of our knowledge the only CYP4V2 disease-causing variant reported in LatinAmerican individuals. The CYP4V2 protein structure presents a transmembrane region at the amino terminal end, followed by a globular structural domain composed of 18 α-helices connected by β-sheet and random coil structures. 5 The heme group resides near the protein surface, between helices I (toward the central core) and L (toward the surface), similarly to other members of the CYP450 superfamily.
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CYP4V2 pathogenic mutations including frameshift, splicing site and nonsense changes impair this highly conserved protein folding. Missense mutations generally affect the transmembrane segment, interfering with the integration of the CYP4V2 protein into the membrane, and in the active site of the enzyme disrupting the coordination of the porphyrin ring needed for its catalytic function. The α-helix supporting the porphyrin ring may also be affected by missense changes. 55 Therefore, all mutations identified in BCD patients likely lead to the loss-offunction of the enzyme. Recently, CYP4V2 has been also detected in human hepatocellular carcinoma -being its expression Li et al 5, 26 , Yin et al 33, 71 , Lai et al 39, 50 , Xiao et al Both CYP4V2 intronic F11 variant CYP4V2-KLKB1-F11 secondary to rs2289252 and the rs2036914 polymorphism (rs13146272) have been also considered as risk factors associated with venous thromboembolism. 62 Genotype -phenotype findings and epigenetic factors
The existence of elevated clinical variability in unrelated BCD individuals harboring the same homozygous mutation or combination of them, and the additional intra-and interfamilial variability in clinical severity suggests the presence of other factors that modulate the disease. 11, 18 Due to the fact that fatty acid metabolism is clearly implicated in the genesis of the disease, healthy diet and good patterns of alimentation, lipid restriction and other environmental factors are suggested to play an additional role in the final phenotypic characterization. targeting the defective epigenetic modulation to correct the altered mechanisms, especially in the early phases of BCD, should be the basis to develop future diagnosis tools and new clinical treatments in order to improve the quality of life of the patients.
Future perspectives in BCD
Genetic counseling for BCD patients and their heterozygous asymptomatic relatives requires detailed record of the family history, disclosing relevant information about the disease and the pattern of inheritance. Genetic testing contributes to clarify the carrier condition of different family members, and is useful to predict the degree of damage and progression rate associated with specific mutations. In addition, genetic counseling allows assessment of a person or couple's BCD risk and the chances that their offspring will inherit CYP4V2 mutations and manifest the disease. Correct family planning requires CYP4V2 genetic testing in partners of heterozygous carriers.
The discovery of accompanying CYP4V2 mutations in patients affected by retinitis pigmentosa, Leber congenital amaurosis (LCA) and other retinal dystrophies 64, 65 reveals the genetic complexity of some genotypes and shows that gene panel-based genetic testing is necessary for reliable retinal dystrophy diagnosis and correct clinical diagnosis of the individuals. Interpretation of possible combinatorial phenotypic effects among different mutations coinherited in these patients is difficult and, therefore, further research is required to clarify this issue. The creation of national and international patient registries and databases in different countries for retinal dystrophies, containing both clinical and genetic information, is key instruments to advance clinical research as well as to improve patient care and health care planning. They allow collecting enough data to achieve sufficient sample sizes for epidemiological and/or clinical research. They also allow assessment of clinical trials feasibility and facilitate the planning of appropriate clinical trials and patient enrolment. Epigenetic alterations are increasingly recognized as important players in the pathogenesis of a growing number of diseases. In this line, CYP4V2 gene activity in BCD patients has historically been thought to be influenced by these mechanisms. To the best of our knowledge, the role of epigenetic factors in BCD has not been investigated, and the reversibility of these alterations provides an excellent opportunity for research and innovation of new therapeutic options for BCD patients. Therefore, the analysis of epigenetic modifications in BCD patients and the study of dietary components, especially lipids, and traditional medicines could contribute to determine the role of epigenetics in this disease.
The recent investigation of Hata et al 53 supports the possible therapeutic effect in BCD patients of intracellular free cholesterol reduction. This type of studies might provide the basis for future medical treatments of BCD. Moreover, further characterization of CYP4V2 catalytic activity and better understanding of the role of this enzyme in BCD pathogenesis may also set the basis to develop novel therapies of this disease. Relevant advances in the treatment of hereditary dystrophies, in particular, LCA type 2 (LCA2), has revitalized the objective of achieving healing of these previously untreatable diseases. RPE65 related LCA2 was successfully treated by gene augmentation surgery using subretinal injections with voretigene neparvovec, 65 a gene therapy based on an adeno-associated vector. This clinical trial led to approval by the US Food and Drug Administration of the Voretigene neparvovec-rzyl treatment. 63 Currently, there are over 100 clinical trials that utilize gene therapy for treating eye disorders, and BCD is included in the Reflection Bio's RBIO-101 program (AAV.CYP4V2), granted by the FDA, to the research and development of an AAV-based gene therapy product for treating the disease. The next step of these development programs is testing the obtained gene therapy in a human clinical trial with BCD patients.
In conclusion, this review provides insights into the current clinical diagnosis and genetic testing of BCD. Despite important advances in this field, BCD remains poorly understood, requiring further efforts to elucidate its precise molecular and biochemical alterations. The long-term goal of this research is to develop different types of personalized medical treatments based on patients' genetic profiles, which hopefully will be achieved in the near future.
